905-P: Clinical Comparison of Infusion Sets with Angled and 90° Teflon Cannulas

Abstract

Objective: Insulin pump users worldwide depend on insulin infusion sets (IISs) for predictable delivery of insulin to the subcutaneous tissue. Yet emerging data indicates that IISs are associated with many pump-related adverse events and may contribute to potentially life-threatening problem of unexplained hyperglycemia. The relative scarcity of published research on IISs to date contributed to the difficulty of IIS section and recommendation. In this cross-over clinical study, a commercial Mio30 infusion set (M30IS) with 30° Teflon cannula was put into head-to-head comparison with a commercial Quick-set infusion set (QIS) with Teflon cannula. Method: This is a cross over study of M30IS and QIS on 20 subjects with Type 1 diabetes. Each subject wore both sets for a month each on a preferred site that was continuously infused with insulin lispro or insulin aspart subcutaneously via a Medtronic 780G pump system for 3 days or until failure. The overall IIS survival rates, glycemic control outcomes (i.e., mean sensor glucose and time spent in established glucose ranges), total daily insulin delivered (TDD), and satisfaction with both IISs were determined. Result: The 20 study subjects comprised of 50% men/women, at 41.3 ± 13.7 years, with BMI 25.7 ± 4.3 and HbA1c 7.0 ± 0.8. Based on the data collected, mean wear duration for the M30IS and QIS was 3.03 and 3.20 days, respectively. The M30IS had slightly more set failures (9.9%) than the QIS (4.4%). TDD and %Time in Range were statistically identical for both M30IS and QIS. Between the two IISs, more people preferred QIS over M30IS Teflon cannula. Conclusion: Choosing between IISs with angled and 90° Teflon cannulas may be a personal preference. In terms of glycemic control, there was no statistical difference between the two IISs. Disclosure O.Cohen: Employee; Medtronic. Y.Cohen: None. S.Chattaraj: Employee; Medtronic. G.Zhang: Employee; Medtronic. E.Anselmo: Employee; Medtronic. A.Tirosh: Advisory Panel; Medtronic, Novo Nordisk, Sanofi, Eli Lilly and Company, Research Support; Medtronic, Sanofi, Speaker's Bureau; Medtronic, Novo Nordisk, Sanofi, Eli Lilly and Company. Funding Medtronic